Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics Inc (NASDAQ: INDP) is a preclinical-stage biotech company pioneering novel immunotherapies that activate both innate and adaptive immune responses. This dedicated news hub provides investors and researchers with essential updates on the company’s innovative bacterial platform and clinical progress.
Access real-time announcements about INDP’s Decoy20 candidate, strategic collaborations, and preclinical findings across multiple cancer types. Our curated collection includes press releases on trial designs, partnership developments, and scientific presentations – all critical for understanding the company’s position in immuno-oncology.
Key updates cover three focus areas: 1) Pipeline advancements in colorectal/pancreatic cancers and lymphoma 2) Mechanism of action insights from TLR/STING pathway activation 3) Strategic initiatives enhancing combination therapy potential. Bookmark this page for unfiltered access to primary source materials that inform investment and research decisions.
Indaptus Therapeutics (Nasdaq: INDP) announced new data from its ongoing Phase 1 trial of Decoy20, presented at the ASCO Annual Meeting on June 1 in Chicago. The data shows that Decoy20 induces significant immune responses in patients with solid tumors, even at varying doses. The treatment was cleared from the blood within 120 minutes and resulted in manageable, lower-grade transient adverse events. Plasma biomarker analysis showed broad immune activation supporting the company’s 'pulse-prime' approach. CEO Jeffrey Meckler expressed optimism about the trial's progress, focusing on the potential anti-tumor activity as patient dosing increases.
Indaptus Therapeutics (Nasdaq: INDP), a clinical-stage biotech firm focused on cancer and viral infection treatments, announces participation in the Jefferies Global Healthcare Conference. CEO Jeffrey Meckler and CMO Dr. Roger Waltzman will present a corporate overview on June 5, 2024, at 8:00 AM ET. The event, held at Marriott Marquis in NYC, includes a live webcast accessible via Indaptus's investor relations webpage, with the replay available for 90 days.
Indaptus Therapeutics (Nasdaq: INDP) unveiled promising new data from their ongoing Phase 1 clinical trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting 2024. The trial involves patients with advanced solid tumors.
The study highlighted Decoy20's pharmacokinetics and immune responses, showing that a single intravenous dose cleared from the bloodstream in 30-120 minutes and prompted the release of over 50 cytokines and chemokines, which are important for immune responses.
Remarkably, Decoy20 maintained a safety profile similar to that of purified lipopolysaccharide (LPS), with adverse effects being generally tolerable and resolving within 90 minutes to 3 days.
Indaptus CMO Roger Waltzman emphasized the significance of these findings and announced that the company would continue with the first multi-dose cohort, with updates expected throughout the year.
Indaptus Therapeutics announced the successful dosing of the first patient in the multi-dose phase of its Phase 1 clinical trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors.
The trial aims to determine the safety and efficacy of Decoy20 when administered multiple times. The initial single-dose phase was well-tolerated, and results will be presented at the ASCO meeting. Decoy20 activates both the innate and adaptive immune systems using broad immune agonists derived from Gram-negative bacteria, aiming to offer a new approach to cancer treatment.
CEO Jeffrey Meckler emphasized the potential of Decoy20 to address unmet medical needs in cancer therapy. The company plans to advance the therapy into combination studies with checkpoint inhibitors based on promising preclinical results.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical development plans. The company announced positive results from its Phase 1 clinical trial of Decoy20 and plans to present a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024. Financially, research and development expenses decreased by 15%, general and administrative expenses decreased by 9%, and loss per share improved. The company had cash and cash equivalents of $9.7 million as of March 31, 2024, with a cash runway expected to support operations through the third quarter of 2024.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
